Picture of BioCryst Pharmaceuticals logo

BCRX BioCryst Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Annual income statement for BioCryst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue25.220.748.817.8157
Cost of Revenue
Gross Profit23.520.244.716.1150
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses82.6115148195279
Operating Profit-57.4-94.2-99.5-177-122
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-65.8-101-109-183-182
Provision for Income Taxes
Net Income After Taxes-65.8-101-109-183-184
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-65.8-101-109-183-184
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-65.8-101-109-183-184
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.779-0.827-0.942-1.08-1.23

Or unlock with your email

Or unlock with your email